- All newly diagnosed breast cancer patients; to define the extent of disease multifocality and/or presence of contralateral abnormalities, and to assist with planning or surgical treatment
- Adjunct to mammography and ultrasound in women with clinically difficult exam and dense breasts on these examinations (women younger than 40)
- Preoperative assessment in patients with mammographic abnormalities or dense breast tissue (i.e., preop breast reduction or revision reconstruction)
- Yearly follow-up for breast cancer patients
- Screening patients at high risk for breast cancer, especially those with suspected or proven mutations of BRCA1 and BRCA2
- Further evaluation of suspicious clinical findings or imaging results that remain indeterminate after mammographic and ultrasound evaluation
- Evaluation of silicone gel implant integrity (supported by recent U.S. Food and Drug Administration recommendations)
- Breast cancer screening in women with breast implants as adjunct to mammography
- Monitor response to neoadjuvant hormonal therapy and/or chemotherapy
- To determine primary site in patients with axillary nodal disease and unknown primary disease
— Dr. Gail Lebovic,
Cooper Clinic, McKinney, TX
